Sharon M. Rymut, PhD

Associate Scientist
Genentech

Disclosure: Genentech (Individual(s) Involved: Self): Employee, Shareholder

Presentation(s):

• 167 - A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple-ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Patients with staphylococcus Aureus Bacteremia Receiving Standard-of-care Antibiotics

  Oral Abstract